Methods of and compositions for stimulation of glucose uptake into muscle cells and treatment of diseases

• US 20070054851A1
• Filed: 05/30/2006
• Published: 03/08/2007
• Est. Priority Date: 05/27/2005
• Status: Abandoned Application

• Current Assignee: Five Prime Therapeutics, Inc. (Amgen Inc.)
• Original Assignee: Five Prime Therapeutics, Inc. (Amgen Inc.)
• Inventors: Wu, Ge, Marshall, Shannon, Hollenbaugh, Diane, Wang, Yan, Doberstein, Stephen, Qin, Minmin, Masuoka, Lorianne, Williams, Lewis, Lin, Junyu, Kothakota, Srinivas, Brennan, Thomas
• Application Number:
  US11/442,244
• Publication Number:
  US 20070054851A1
• Time in Patent Office: Days
• US Class Current: 424/178.100
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 31/155 Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
• CPC Class Codes: A61K 31/18 Sulfonamides compounds containing a para-N-benzene-sulfonyl-N- group A61K31/63
• CPC Class Codes: A61K 31/195 having an amino group
• CPC Class Codes: A61K 31/197 the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid carnitine A61K31/205
• CPC Class Codes: A61K 38/1808 Epidermal growth factor [EGF] urogastrone
• CPC Class Codes: A61K 38/1883 Neuregulins, e.g.. p185erbB2 ligands, glial growth factor, heregulin, ARIA, neu differentiation factor
• CPC Class Codes: A61K 38/26 Glucagons
• CPC Class Codes: A61K 38/28 Insulins
• CPC Class Codes: A61K 45/06 Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• CPC Class Codes: A61K 47/60 the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
• CPC Class Codes: A61P 11/00 Drugs for disorders of the respiratory system
• CPC Class Codes: A61P 13/12 of the kidneys
• CPC Class Codes: A61P 21/00 Drugs for disorders of the muscular or neuromuscular system
• CPC Class Codes: A61P 3/04 Anorexiants; Antiobesity agents
• CPC Class Codes: A61P 3/10 for hyperglycaemia, e.g. antidiabetics
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: A61P 9/10 for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Abstract

The present invention relates to therapeutic uses of ErbB ligands, including betacellulin. The therapeutic uses include methods of using ErbB ligand family compounds alone, or in conjunction with other agents, for reducing blood glucose levels, treating Type I and Type II diabetes, obesity, muscle wasting diseases, and cardiotoxicity.

Claims

1. A pharmaceutical composition comprising a concentration of betacellulin or an active variant or fragment thereof, wherein the concentration is sufficient to acutely reduce the blood glucose level in a subject without inducing hypoglycemia, and a pharmaceutically acceptable carrier.

2. A pharmaceutical composition comprising a concentration of long-acting betacellulin fusion protein comprising a betacellulin polypeptide or an active variant or fragment thereof and a fusion partner, wherein the betacellulin fusion protein has an extended half-life in a subject when compared to the betacellulin polypeptide alone, wherein the concentration is sufficient to perform an action selected from stimulating glucose or amino acid uptake into muscle cells, promoting cell survival or inhibiting apoptosis of muscle cells, inducing utrophin expression, inhibiting muscle wasting or increasing muscle mass, reducing HbA1c, reducing hypoglycemia associated with insulin administration, reducing the basal blood glucose level, and/or acutely reducing the elevated blood glucose level in the subject;

and a pharmaceutically acceptable carrier.

3. The long-acting betacellulin fusion protein of claim 2, wherein the extended half-life comprises at least 0.5 hr, at least 1 hr, at least 2 hr, at least 3 hr, at least 4 hr, or at least 5 hr longer than the half-life of the betacellulin polypeptide alone.

4. The long-acting betacellulin fusion protein of claim 2, wherein the fusion partner is a polymer, a polypeptide, a succinyl group, or an active variant or fragment of any of these.

5. The long-acting betacellulin fusion protein of claim 4, wherein the fusion partner polymer comprises a polyethylene glycol moiety either permanently or reversibly covalently attached to the betacellulin polypeptide.

6. The long-acting betacellulin fusion protein of claim 4, wherein the fusion partner polypeptide comprises an immunoglobulin fragment, albumin, or an oligomerization domain.

7. The long-acting betacellulin fusion protein of claim 6, wherein the immunoglobulin fragment comprises an Fc fragment.

8. A kit comprising:

(a) a pharmaceutical composition comprising a polypeptide of the ErbB ligand family or an active variant or fragment thereof, either alone or as part of a long-acting fusion protein, wherein the fusion protein has an extended half-life in a subject when compared to the ErbB ligand polypeptide alone;

and a pharmaceutically acceptable carrier; and

(b) instructions for administration into a subject in need of such a composition.

9. The kit of claim 8 wherein the polypeptide of the ErbB ligand family is selected from betacellulin, neuregulin1, HB-EGF, EGF, TGF-alpha, epiregulin, epigen, and amphiregulin.

10. The kit of claim 8 wherein the polypeptide is betacellulin.

11. The kit of claim 8, wherein the instructions describe a use for the composition selected from stimulating glucose or amino acid uptake into muscle cells, reducing HbA1c, reducing hypoglycemia associated with insulin administration, reducing the basal blood glucose level, acutely reducing the elevated blood glucose level, promoting cell survival or inhibiting apoptosis of muscle cells, inducing utrophin expression, inhibiting muscle wasting or increasing muscle mass, and treating the subject for obesity.

12. The kit of claim 8, further comprising a vial or cartridge.

13. The kit of claim 12, wherein the vial or cartridge comprises a concentration of the ErbB ligand polypeptide selected from about 50 micrograms/milliliter to about 100 micrograms/milliliter, from about 100 micrograms/milliliter to about 1 milligram/milliliter, from about 1 milligram/milliliter to about 5 milligrams/milliliter, and from about 5 milligrams/milliliter to about 500 milligrams/milliliter ErbB ligand polypeptide.

14. The kit of claim 13, wherein the vial or cartridge comprises from about 100 milligrams/milliliter to about 400 milligrams/milliliter ErbB ligand polypeptide.

15. The kit of claim 13, wherein the vial or cartridge comprises from about 200 milligrams/milliliter to about 300 milligrams/milliliter ErbB ligand polypeptide.

16. The kit of any of claims 12-15, wherein the vial or cartridge comprises a single dose of ErbB ligand polypeptide with a volume of about 0.5 milliliters, about 1.0 milliliter, or about 1.5 milliliters.

17. The kit of any of claims 12-15, wherein the vial or cartridge comprises a single dose, a double dose, or a triple dose of the ErbB ligand polypeptide.

18. The kit of claim 8, further comprising at least one second agent, wherein the second agent is an anti-diabetic agent.

19. A method of treating a disease in a subject comprising:

(a) providing a polypeptide of the ErbB ligand family; and

(b) administering the polypeptide to the subject,

wherein the subject has normal pancreatic function and/or a normal insulin level and wherein the subject would benefit from an action selected from stimulating glucose or amino acid uptake into muscle cells, reducing HbA1c, reducing hypoglycemia associated with insulin administration, reducing the basal blood glucose level, acutely reducing the elevated blood glucose level, promoting cell survival or inhibiting apoptosis of muscle cells, inducing utrophin expression, and inhibiting muscle wasting or increasing muscle mass.

20. The method of claim 19 wherein the polypeptide is selected from betacellulin, neuregulin1, HB-EGF, EGF, TGF-alpha, epiregulin, epigen, and amphiregulin.

21. The method of claim 19, wherein the polypeptide comprises betacellulin or an active variant or fragment thereof.

22. The method of claim 19, wherein the polypeptide comprises a long-acting fusion protein comprising a polypeptide of the ErbB ligand family or an active variant or fragment thereof and a fusion partner, wherein the ErbB ligand fusion protein has an extended half-life in a subject when compared to the ErbB ligand polypeptide alone.

23. The method of claim 19, wherein the disease comprises an elevated blood glucose level.

24. The method of claim 23, wherein the disease comprises Type I or Type II diabetes.

25. The method of claim 19, wherein the disease has symptoms selected from acute hyperglycemia, incipient diabetic ketoacidosis, diabetic ketoacidosis, and diabetic coma.

26. The method of claim 23, wherein the polypeptide is administered at a dose sufficient to produce a euglycemic level of blood glucose, to lower fasting blood glucose and/or lower the HbA1c level in the subject.

27. The method of claim 19, wherein the disease comprises obesity.

28. The method of claim 19, wherein the disease is selected from diabetic amyotrophy or other metabolic myopathy, cachexia, AIDS wasting, disuse atrophy, sarcopenia, rhabdomyolysis, myositis, diaphragmatic weakness due to muscular disorder, and muscular dystrophy.

29. The method of claim 19, wherein the muscle cells affected by the polypeptide are selected from skeletal, cardiac, and smooth muscle.

30. The method of claim 19, wherein the cells into which the uptake of glucose or amino acid is stimulated are cardiac cells and wherein the disease comprises a cardiac disease.

31. The method of claim 30, wherein the cardiac disease is selected from ischemia, congestive heart failure, myocardial infarction, and induced cardiotoxicity.

32. The method of claim 31, wherein the induced cardiotoxicity is induced by chemotherapy or is virally induced.

33. The method of claim 30, wherein the polypeptide is administered as a composition comprising a collagen or a gel.

34. The method of claim 19, wherein the subject is treated in an emergency setting.

35. The method of claim 34, wherein the emergency setting is selected from an emergency room, an intensive care setting, a setting wherein the subject is acutely ill, and a setting wherein the subject is suffering from a condition selected from respiratory failure, cardiac failure, kidney failure, diabetic ketoacidosis, and another life-threatening condition.

36. The method of claim 19, wherein the polypeptide is administered orally, subcutaneously, intravenously, transdermally, intraperitoneally, by inhalation, by implantation, intradermally, intramuscularly, intracardially, nasally, and/or by rectal suppository.

37. The method of claim 19, wherein the polypeptide is administered at a dose sufficient to produce a blood concentration of the polypeptide in a range from about 1 nanomolar to about 10 nanomolar or from about 10 nanograms/milliliter to about 100 nanograms/milliliter in the subject.

38. The method of claim 19, wherein the polypeptide is administered at least once a day, at least two times a day, or at least three times a day.

39. The method of claim 19, wherein one dose of the polypeptide is administered at or about meal time.

40. The method of claim 19, wherein the polypeptide is administered at a time selected from within about 120 minutes, about 90 minutes, about 60 minutes, about 30 minutes, about 15 minutes, or about 5 minutes before or after a meal;

or during a meal.

41. The method of claim 19, wherein the benefit comprises acute reduction of elevated blood glucose level.

42. The method of claim 41, wherein the acute reduction occurs in a time period selected from within about 1 minute to about 120 minutes, within about 2 minutes to about 90 minutes, within about 3 minutes to about 60 minutes, within about 4 minutes to about 30 minutes, and within about 5 minutes to about 15 minutes.

43. The method of claim 19, wherein the polypeptide is administered in one or more doses, selected from a dose comprising from more than about 50 micrograms to less than about 2 milligrams, greater than about 2 milligrams to less than about 10 milligrams, and greater than about 10 milligrams to about 500 milligrams.

44. The method of claim 43, wherein the dose comprises from about 100 milligrams to about 400 milligrams.

45. The method of claim 44, wherein the dose comprises from about 200 milligrams to about 300 milligrams.

46. The method of claim 19, wherein the polypeptide is administered in one or more doses, selected from doses comprising from about 0.01 milligrams/kilogram to about 5 milligrams/kilogram, from about 0.1 milligrams/kilogram to about 2 milligrams/kilogram, from about 0.2 milligrams/kilogram to about 1 milligram/kilogram, from about 0.3 milligrams/kilogram to about 0.9 milligrams/kilogram, from about 0.4 milligrams/kilogram to about 0.8 milligrams/kilogram, and from about 0.5 milligrams/kilogram to about 0.7 milligrams/kilogram.

47. The method of claim 46, wherein the dose comprises no more than 1 milligram/kilogram.

48. The method of claim 19, wherein the polypeptide is administered in one or more doses, each comprising from about 1 microgram/kilogram to about 10 milligrams/kilogram.

49. The method of claim 48, wherein the polypeptide is administered in one or more doses, each comprising from about 10 micrograms/kilogram to about 1 milligram/kilogram.

50. The method of claim 19, further comprising:

(c) administering at least one second agent, wherein the second agent is another therapeutic agent.

51. The method of claim 50, wherein the second agent comprises an anti-diabetic agent.

52. The method of claim 50 or 51, wherein the second agent is administered orally, subcutaneously, intravenously, transdermally, intraperitoneally, by inhalation, by implantation, intradermally, intramuscularly, intracardially, nasally, and/or by rectal suppository.

53. The method of claim 50 or 51, wherein the second agent is administered before, after, or at the same time as the polypeptide.

54. The method of claim 50, wherein the second agent is selected from metformin, an insulin secretagogue, a glucosidase inhibitor, a PPAR gamma, and a dual PPAR gamma/alpha-agonist.

55. The method of claim 54, wherein the insulin secretagogue is selected from a sulfonylurea and a meglitinide.

56. The method of claim 50, wherein the second agent is selected from insulin, an insulin analogue, a co-secreted agent, pramlinitide, and a DPP4 antagonist.

57. The method of claim 50, wherein the second agent comprises a glucagon-like peptide.

58. The method of claim 57, wherein the glucagon-like peptide comprises exenatide.